Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Political uncertainty, especially with Trump’s election, has also made investors nervous. In 2024, Novo Nordisk A/S (NYSE:NVO) raised its total dividend per share by 21.3% to DKK 11.40 ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

It has been about 100 years since Novo Nordisk marketed the first effective drug for diabetes, and although tremendous progress has been made, the Danish company is never fully satisfied.

Novo Nordisk announced on Wednesday that it will conduct additional trials for its next-generation obesity drug candidate, CagriSema. The new trials will explore dose escalation and trial length to ...